Calendar

pharmadog

Week of Oct 13, 2025

Oct 16, 2025approval318d agoYUFLYMA (ADALIMUMAB-AATY) — FDA approvalYUFLYMA

Sponsor: CELLTRION. Form: INJECTABLE. Route: INJECTION

full page →YUFLYMA →fda approvals ↗

Oct 17, 2025approval317d agoVYVGART HYTRULO (EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC) — FDA approvalARGENX SE

Sponsor: ARGENX BV. Form: INJECTABLE. Route: INJECTION

full page →fda approvals ↗

Oct 17, 2025approval317d agoOZEMPIC (SEMAGLUTIDE) — FDA approvalNovo Nordisk AS

Sponsor: NOVO. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Oct 17, 2025approval317d agoOZEMPIC (SEMAGLUTIDE) — FDA approvalNovo Nordisk AS

Sponsor: NOVO. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Oct 17, 2025approval317d agoOZEMPIC (SEMAGLUTIDE) — FDA approvalNovo Nordisk AS

Sponsor: NOVO. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Oct 17, 2025approval317d agoOXYMORPHONE HYDROCHLORIDE — FDA approvalAmneal Pharmaceuticals, Inc.

Sponsor: IMPAX LABS. Form: TABLET, EXTENDED RELEASE. Route: ORAL

full page →fda approvals ↗

Oct 17, 2025approval317d agoGAZYVA (OBINUTUZUMAB) — FDA approvalobinutuzumab

Sponsor: GENENTECH. Form: INJECTABLE. Route: INJECTION

full page →obinutuzumab →fda approvals ↗

Oct 17, 2025approval317d agoGAZYVA (OBINUTUZUMAB) — FDA approvalobinutuzumab

Sponsor: GENENTECH. Form: INJECTABLE. Route: INJECTION

full page →obinutuzumab →fda approvals ↗

Oct 17, 2025approval317d agoBALVERSA (ERDAFITINIB) — FDA approvalerdafitinib

Sponsor: JANSSEN BIOTECH. Form: TABLET. Route: ORAL

full page →erdafitinib →fda approvals ↗

Oct 17, 2025approval317d agoTEZSPIRE (TEZEPELUMAB-EKKO) — FDA approvaltezepelumab

Sponsor: ASTRAZENECA AB. Form: SOLUTION. Route: SUBCUTANEOUS

full page →tezepelumab →fda approvals ↗

Oct 17, 2025approval317d agoHADLIMA (ADALIMUMAB-BWWD) — FDA approvalHADLIMA

Sponsor: SAMSUNG BIOEPIS CO LTD. Form: INJECTABLE. Route: INJECTION

full page →HADLIMA →fda approvals ↗

Oct 17, 2025approval317d agoCLOMIPHENE CITRATE — FDA approvalCLOMIPHENE CITRATE

Sponsor: NOVITIUM PHARMA. Form: TABLET. Route: ORAL

full page →CLOMIPHENE CITRATE →fda approvals ↗

Oct 17, 2025approval317d agoTRIAMCINOLONE ACETONIDE — FDA approvaltriamcinolone acetonide Rising

Sponsor: ALEMBIC. Form: INJECTABLE. Route: INJECTION

full page →triamcinolone acetonide Rising →fda approvals ↗

Oct 17, 2025approval317d agoBUCAPSOL (BUSPIRONE HYDROCHLORIDE) — FDA approvalBUSPIRONE HYDROCHLORIDE

Sponsor: EPIC PHARMA LLC. Form: CAPSULE. Route: ORAL

full page →BUSPIRONE HYDROCHLORIDE →fda approvals ↗

Oct 17, 2025approval317d agoEPIOXA HD/EPIOXA KIT (RIBOFLAVIN 5'-PHOSPHATE SODIUM) — FDA approvalriboflavin 5'-phosphate sodium

Sponsor: GLAUKOS. Form: SOLUTION/DROPS. Route: OPHTHALMIC

full page →riboflavin 5'-phosphate sodium →fda approvals ↗

Oct 17, 2025approval317d agoPOMALIDOMIDE — FDA approvalPOMALIDOMIDE

Sponsor: MYLAN. Form: CAPSULE. Route: ORAL

full page →POMALIDOMIDE →fda approvals ↗

Oct 17, 2025approval317d agoVYVGART (EFGARTIGIMOD ALFA) — FDA approvalARGENX SE

Sponsor: ARGENX BV. Form: INJECTABLE. Route: INJECTION

full page →fda approvals ↗

Oct 17, 2025approval317d agoTACROLIMUS — FDA approvaltacrolimus ER

Sponsor: GLENMARK PHARMS LTD. Form: CAPSULE. Route: ORAL

full page →tacrolimus ER →fda approvals ↗

Oct 17, 2025approval317d agoTACROLIMUS — FDA approvaltacrolimus ER

Sponsor: GLENMARK PHARMS LTD. Form: CAPSULE. Route: ORAL

full page →tacrolimus ER →fda approvals ↗

Oct 17, 2025approval317d agoTACROLIMUS — FDA approvaltacrolimus ER

Sponsor: GLENMARK PHARMS LTD. Form: CAPSULE. Route: ORAL

full page →tacrolimus ER →fda approvals ↗

Oct 17, 2025approval317d agoTACROLIMUS — FDA approvaltacrolimus ER

Sponsor: GLENMARK PHARMS LTD. Form: CAPSULE. Route: ORAL

full page →tacrolimus ER →fda approvals ↗

Week of Oct 20, 2025

Oct 20, 2025approval314d agoBEYFORTUS (NIRSEVIMAB-ALIP) — FDA approvalnirsevimab

Sponsor: ASTRAZENECA AB. Form: INJECTABLE. Route: INJECTION

full page →nirsevimab →fda approvals ↗

Oct 20, 2025approval

← prev

page 383 of 475

Week of Oct 13, 2025

Week of Oct 20, 2025